Monsenso ApS receives CE Marking for its mobile health solution for mental illnesses
Copenhagen, Denmark — 16 February 2016. Monsenso, a technology leader in mobile health solutions for mental health, today announced that last Friday, its double-loop treatment solution that supports the treatment of major psychiatric disorders received the CE Marking Certification under the EU Medical Devices Directive.
The certification has been obtained due to the support received from the Market Development Fund (MMF) in May 2015, which granted 2.9 million to DKK for Monsenso and its partners to obtain the necessary certifications for the solution to be ready for an international launch.
With regards to obtaining the CE Marking Certification, Thomas Lethenborg, CEO at Monsenso, commented “Obtaining this certification is an important milestone for Monsenso since our mHealth solution is based on solid research and has already been clinically validated. Our objective with this certification is to be regarded as a medical application rather than just another app.”
A CE Marking Certification guarantees that a manufacturer’s product meets the essential requirements of all relevant European Medical Device Directives.
To continue reading click on this link: http://www.monsenso.com/smartphone-app-mhealth-solution-for-mental-illness-with-ce-marking/
Monsenso is an innovative technology company offering an mHealth solution to help optimize the treatment of mental disorders. Our mission is to help healthcare providers, researchers, and individuals overcome the burden of mental illness. Our solution provides a detailed overview of a patient’s mental health through the collection of behavioural data and self-monitoring. Based on continued research and development, our team is committed to developing comprehensive solutions that fit seamlessly into the lives of individuals, increasing the quality and efficacy of their treatment. To learn more visit www.monsenso.com